IN8bio, Inc.
- INAB
- NASDAQ
- Biotechnology
- Gamma-Delta T Cell Therapy
- Cancer Immunotherapy
$1.11
Today −6.33%Quote Oct 16, 2026, 08:00 PM UTC
+3.74%over the last month
Max drawdown −21.8%From 1-month high −21.8%3 months −11.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$10.9M
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$4.00
+260.4% from here
Floor
$1.10
0.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INABPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
18